SCHEMBL11901969

SCHEMBL11901969

C[C@H](NC(=O)OC(C)(C)C)c1nc2ccc(F)cc2n1C1CC(OCc2ccccc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.41
BACE2 Q9Y5Z0 1/20 0.41
BRD4 O60885 1/20 0.38
KLK7 P49862 4/20 0.36
KLK5 Q9Y337 3/20 0.36
PIK3CD O00329 1/20 0.36
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
IDO1 P14902 2/20 0.36
KCNH2 Q12809 1/20 0.36
ATM Q13315 2/20 0.36
MAPT P10636 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
CTSL P07711 1/20 0.36
PPARA Q07869 1/20 0.35
ACACB O00763 2/20 0.35
JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11902027 1.00 BACE1 (0.41) BACE1BACE2BRD4KLK7KLK5
SCHEMBL11901971 1.00 BACE1 (0.41) BACE1BACE2BRD4KLK7KLK5
SCHEMBL11901639 0.86 PIK3CD (0.40) BRD4PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL11900899 0.86 PIK3CD (0.40) BRD4PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL11900901 0.86 PIK3CD (0.40) BRD4PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL2507650 0.83 PIK3CD (0.49) BRD4PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL2507652 0.83 PIK3CD (0.49) BRD4PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL11900545 0.83 BACE1 (0.45) BACE1BACE2ATM
SCHEMBL11901298 0.82 PIK3CD (0.46) BRD4PIK3CDPIK3R1PIK3CAPIK3CB
SCHEMBL11902050 0.81 PIK3CD (0.45) BRD4PIK3CDPIK3R1PIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 BACE1 371/4885BACE2 890/4885BRD4 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.